• The total number of incident cases of AML (excluding APL) in the European countries under study will increase by 17% over the forecast period, from 4,700 in 2017 to 5,400 in 2027.
  • The total number of incident cases of APL in the European countries under study will increase by 1% over the forecast period, from 310 in 2017 to 320 in 2027.
  • 25% of the diagnosed incident cases of AML have FLT3-ITD mutations, and 5% have FLT3-TKD mutations.

Table of contents

  • Acute Myeloid Leukemia - Epidemiology - Europe Data
    • Introduction
      • Key Findings
        • Overview
          • Diagnosed Incidence of Acute Myeloid Leukemia per 100,000 People of All Ages per Year in 2017 and 2027
          • Diagnosed Incidence of Acute Promyelocytic Leukemia per 100,000 People of All Ages per Year in 2017 and 2027
          • Relative Sizes of the Factors Contributing to the Trend in Incident Cases of Acute Myeloid Leukemia over the Next Ten Years
          • Relative Sizes of the Factors Contributing to the Trend in Incident Cases of Acute Promyelocytic Leukemia over the Next Ten Years
      • Epidemiology Data
      • Methods
        • Diagnosed Prevalent Cases
        • Newly Diagnosed Incident Cases
        • FLT-3 Mutation
        • Lifetime DALYs Gained
      • Reference Materials
        • Literature Review
          • Studies Included in the Analysis of Acute Myeloid Leukemia
          • Studies Excluded from the Analysis of Acute Myeloid Leukemia
        • Risk/Protective Factors
          • Risk/Protective Factors for Acute Myeloid Leukemia
        • Bibliography

    Author(s): Mike Hughes, MSc, PhD; Atul Sharma, MPH; Oliver Blandy

    Mike joined Decision Resources as an epidemiologist in 2006. He has many years’ experience in the mathematical modeling of healthcare service delivery, cardiovascular and cancer epidemiology, biostatistics, meta-analysis and systematic reviewing.

    He has been principal author on many published articles in leading international journals in the areas of risk modeling in intensive care and cardiovascular medicine. He has also been responsible for developing national guidelines on behalf of NICE and the American College of Chest Physicians for the treatment of atrial fibrillation, stroke and hypertension. He is particularly interested in modeling patient flows in cancer and methods for forecasting disease burden in non-communicable epidemiology.

    Dr. Hughes received his Ph.D. in risk modeling in intensive care in 2003 from City University, London and is currently enrolled in a Ph.D. program in statistical causation and foundations of probability theory at the University of Nottingham.

    Atul Sharma started working in Decision Resources Group as an intern in early 2016 and currently works as an associate epidemiologist. He performs fully documented systematic reviews of both published and grey literature on the epidemiology of assigned diseases and their risk factors to estimate incidence/prevalence over a 10-30 year period. He produces analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets.

    He holds a Master’s in Public Health degree from School of Public Health, Post-Graduate Institute of Medical Education and Research and a Bachelor’s in dental surgery from MN DAV Dental College & Hospital.

    Oliver Blandy, BSc PGCE MSc, joined Decision Resources Group (DRG) as an Associate Epidemiologist in 2017. He focuses on the epidemiology of cancer.

    Oliver holds an MSc from the University of Bristol where he specialized in Nutrition, Physical Activity and Public Health. He also holds a BSc in Chemistry and has a Post Graduate Certificate in Education (PGCE), both from the University of Bristol and taught general science and Advanced Chemistry in high school for two years.

    Before joining the team at DRG, Oliver worked as a Research Assistant for Imperial College London where he was the lead for several studies within an NIRH funded research group that investigated healthcare associated infections and antimicrobial resistance.


    Related Reports

    Acute Myeloid Leukemia - Landscape & Forecast - Disease Landscape & Forecast

    Acute myeloid leukemia (AML) is the most common form of leukemia in adults and has historically been associated with poor five-year overall survival rates. In recent years, the AML treatment a...

    View Details

    Acute Myeloid Leukemia - Current Treatment - Detailed, Expanded Analysis: Treatment Sequencing (US)

    KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.

    View Details

    Acute Myeloid Leukemia | Disease Landscape and Forecast | G7 | 2020

    Acute myeloid leukemia (AML), the most common form of leukemia in adults, has historically been associated with poor five-year overall survival rates. AML is witnessing a paradigm shift from c...

    View Details

    Acute Myeloid Leukemia - Geographic Focus: China - Acute Myeloid Leukemia | China In-Depth | China

    Acute myeloid leukemia (AML) is the most common form of adult leukemia but has the lowest five-year overall survival rates of all blood cancers. Historic...

    View Details